UNSPSC 51332206: Carpipramine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4-bipiperidine)-4-carboxamide dihydrochloride monohydrate but more generally known as carpipramine dihydrochloride, which bears US NIH Compound Identifier 23476.

European Medicines Agency schedules Carpipramine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01067MIG. Most nations, for tariff and trade purposes, schedule carpipramine hydrochloride under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.O.CL.CL.

UNSPSC 51332206 Carpipramine hydrochloride is a Commodity code that nominally identifies a single pharmaceutical active ingredient, but recent state and local solicitations posted under this code do not reflect procurement of carpipramine specifically. Instead, the opportunities tagged to this code cover broader pharmaceutical and drug-management procurement — notably naloxone and safe drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers. This mismatch suggests either miscoding of opportunities at the source or a data-quality issue in the indexing of these procurements to the carpipramine commodity code. State and local bodies issuing under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon participation). The geographic spread of recent activity covers Florida, Texas, Minnesota, and Oregon, with MMCAP's multistate model suggesting broader regional participation across cooperative purchasing members.

Representative recent opportunities include Seminole County's IFB for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries due by July 26, 2023; the Texas HHS Commission's RFI (HHS0017013) seeking vendor capabilities for direct-to-manufacturer prescription programs, with responses due April 3, 2026; and MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, establishing contracts effective July 1, 2026. The MMCAP procurement emphasizes compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, requires pricing submission through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), and evaluates vendors on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and price competitiveness (75 percent). Given the evident mismatch between the code's nominal scope and actual recent solicitations, this code shows little relevant activity for carpipramine-specific procurement.